Stock CLCS CELL SOURCE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cell Source, Inc.

Equities

CLCS

US15114L1044

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 14:57:38 2024-04-19 EDT 		5-day change 1st Jan Change
0.0002 USD -99.95% Intraday chart for Cell Source, Inc. -.--% -99.96%
03-22 Cell Source, Inc. announced that it has received $4.76017 million in funding CI
2023 Cell Source, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 6.596 19.34 29.13 63.92 43.22 29.96
Enterprise Value (EV) 1 8.546 22.09 31.8 68.58 49.62 37.65
P/E ratio -2.18 x -8.04 x -5.97 x -10.7 x -6.58 x -4.68 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA -3.73 x -11 x - - - -
EV / FCF -4.53 x -12.2 x -39.4 x -44.2 x -22.8 x -28.2 x
FCF Yield -22.1% -8.17% -2.54% -2.26% -4.38% -3.55%
Price to Book -1.5 x -3.97 x -5.19 x -8.19 x -4.48 x -2.43 x
Nbr of stocks (in thousands) 24,429 25,781 26,479 31,960 33,752 35,252
Reference price 2 0.2700 0.7500 1.100 2.000 1.280 0.8500
Announcement Date 18-07-25 19-04-01 20-03-30 21-04-15 22-04-15 23-08-08
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales - - - - - -
EBITDA 1 -2.292 -2.006 - - - -
EBIT 1 -2.293 -2.006 -3.805 -3.638 -4.019 -4.175
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -3.083 -2.117 -4.475 -4.56 -5.472 -5.168
Net income 1 -3.083 -2.117 -4.475 -4.56 -5.472 -5.168
Net margin - - - - - -
EPS 2 -0.1241 -0.0932 -0.1842 -0.1869 -0.1946 -0.1816
Free Cash Flow 1 -1.887 -1.804 -0.8061 -1.552 -2.176 -1.336
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 18-07-25 19-04-01 20-03-30 21-04-15 22-04-15 23-08-08
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 1.95 2.75 2.67 4.66 6.4 7.68
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) -0.8507 x -1.373 x - - - -
Free Cash Flow 1 -1.89 -1.8 -0.81 -1.55 -2.18 -1.34
ROE (net income / shareholders' equity) 57.1% 44.7% 84% 66.6% 61.6% 46%
ROA (Net income/ Total Assets) -386% -420% -2,634% -802% -656% -721%
Assets 1 0.7989 0.5045 0.1699 0.5687 0.8346 0.7165
Book Value Per Share 2 -0.1800 -0.1900 -0.2100 -0.2400 -0.2900 -0.3500
Cash Flow per Share 2 0.0100 0 0 0.0100 0 0.0100
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 18-07-25 19-04-01 20-03-30 21-04-15 22-04-15 23-08-08
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CELL SOURCE, INC. Stock Cell Source, Inc.
-99.96% 8.2K
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+2.93% 106B
ARGENX SE Stock argenx SE
+7.02% 23.47B
BIONTECH SE Stock BioNTech SE
-14.60% 21.9B
GENMAB A/S Stock Genmab A/S
-7.05% 18.77B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.55% 17.85B
BEIGENE, LTD. Stock BeiGene, Ltd.
-8.83% 16.78B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.51% 14.41B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.49% 12.86B
VIKING THERAPEUTICS, INC. Stock Viking Therapeutics, Inc.
+329.39% 8.78B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CLCS Stock
  4. Financials Cell Source, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW